X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

CVAC

Closed

Curevac Nv

5.41
-0.02 (-0.37%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 5.43
Day's Range: 5.37 - 5.45
Send
When Written:
 
6.97
CureVac NV is a biotechnology company based in Tübingen, Germany, that specializes in developing messenger RNA (mRNA) therapeutics and vaccines for various diseases. The company was founded in 2000 by Ingmar Hoerr, Florian von der Mülbe, and Steve Pascolo.

CureVac's mRNA technology platform allows the company to create vaccines and therapeutics that can be rapidly developed and produced, with the potential to address a wide range of diseases. The company's lead product candidate is a COVID-19 vaccine, which is currently in Phase 3 clinical trials.

In addition to its COVID-19 vaccine program, CureVac is also developing mRNA-based therapies for cancer and rare diseases. The company has partnerships with several pharmaceutical companies, including GlaxoSmithKline, Bayer, and Genmab, to develop and commercialize its products.

CureVac went public on the Nasdaq stock exchange in August 2020, raising $213 million in its initial public offering. The company has a market capitalization of approximately $14 billion as of August 2021.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X